References
- Cavattoni I, Zabelina T, Ayuk F, et al Letter to the editor:pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell-lymphoma afterallogeneic stem cell transplantation. Leuk Lymphoma 2010;51:146–148.
- Van Besien K, Carreras J, Bierman PJ, et al Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transpl 2009;15:554–563.
- Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using afludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transpl 2000;25:1021–1028.
- Slavin S, Nagler A. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Ann Oncol.1998;9 (Suppl 1):S31–S39.
- Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997;89 : 3951–3959.
- Nagler A, Berger R, Ackerstein A, et al A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant Interferon α(IFN-α) versus no immunotherapy for patients with malignant lymphoma post autologous stem cell transplantation. J Immunotherapy , in press.
- Slavin S, Naparstek E, Nagler A, et al Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195–2004.
- Shimoni A, Hardan I, Avigdor A. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003;122:457–464.
- Cutler C, Miklos D, Kim HT, et al Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756–762.
- Shimoni A, Zwas ST, Oksman Y, et al Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transpl 2008;41:355–361.
- Berger R, Rotem-Yehudar R, Slama G, et al Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044–3051.